LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

Inicio・Lista de Acciones・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Abierto

SectorSanidad

155.43 1.89

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

151.1

Máximo

155.35

Métricas clave
By Trading Economics
Ingresos	-89M -454M
BPA	-2.29
Empleados	883
EBITDA	-92M -441M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+21.37% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	3.4B 35B
Apertura anterior	153.54
Cierre anterior	155.43

Noticias sobre sentimiento de mercado

By Acuity

50%

147 / 344 Clasificación en Healthcare

REVOLUTION Medicines Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 ene 2026, 11:10 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

7 ene 2026, 20:13 UTC

Principales Movimientos del Mercado

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

17 oct 2025, 18:13 UTC

Principales Movimientos del Mercado

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

26 ene 2026, 09:55 UTC

Acciones populares

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

25 ene 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 ene 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 ene 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

9 ene 2026, 19:58 UTC

Adquisiciones, fusiones, absorciones

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 ene 2026, 14:54 UTC

Adquisiciones, fusiones, absorciones

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 ene 2026, 10:54 UTC

Adquisiciones, fusiones, absorciones

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

8 ene 2026, 14:49 UTC

Adquisiciones, fusiones, absorciones

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

8 ene 2026, 12:38 UTC

Adquisiciones, fusiones, absorciones

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

7 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 ene 2026, 20:29 UTC

Adquisiciones, fusiones, absorciones

AbbVie Near Deal for Revolution Medicines -- Update

7 ene 2026, 19:48 UTC

Adquisiciones, fusiones, absorciones

Revolution Has Market Value of Around $16B -- WSJ

7 ene 2026, 19:48 UTC

Adquisiciones, fusiones, absorciones

AbbVie Near Deal for Revolution Medicines -- WSJ

7 ene 2026, 19:48 UTC

Adquisiciones, fusiones, absorciones

Deal May Come Soon, Sources Say -- WSJ

7 ene 2026, 19:48 UTC

Adquisiciones, fusiones, absorciones

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Comparación entre iguales

Cambio de precio

REVOLUTION Medicines Inc previsión

Precio Objetivo

By TipRanks

21.37% repunte

Estimación a 12 Meses

Media 183.65 USD 21.37%

Máximo 263 USD

Mínimo 140 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

Comprar

Mantener

Vender

De acuerdo con 21 analistas que ofrecen calificaciones bursátiles a para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

147 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.